Fortis Healthcare

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Doctors at Fortis Memorial Research Institute (FMRI), Gurugram give new lease of life to 3 young Iraqi thalassemia patients from same family via rare BMT Procedure

Retrieved on: 
Thursday, October 12, 2023
Diagnosis, Parent, Family, Sibling, Hematology, Heart, Ageing, Survival, Fortis Healthcare, Iron overload, Transplant, FMRI, Bone marrow, Gene, BMT, Patient, Dentistry, Thalassemia

The family of the 3 Iraqi patients was counseled and explained in detail about all the pros and cons pertaining to stem cell transplant.

Key Points: 
  • The family of the 3 Iraqi patients was counseled and explained in detail about all the pros and cons pertaining to stem cell transplant.
  • After getting informed consent, all three were admitted for a matched sibling donor stem cell transplant, which went off successfully.
  • Speaking about the rare BMT procedure, Dr Vikas Dua said, "The uniqueness about these 3 patients was their younger age.
  • Fortis Gurugram has a dedicated team of Hematologists alongwith the best of medical infrastructure to treat the most complex cases.

Doctors at Fortis Memorial Research Institute (FMRI), Gurugram give new lease of life to 3 young Iraqi thalassemia patients from same family via rare BMT Procedure

Retrieved on: 
Thursday, October 12, 2023
Diagnosis, Parent, Family, Sibling, Hematology, Heart, Ageing, Survival, Fortis Healthcare, Iron overload, Transplant, FMRI, Bone marrow, Gene, BMT, Patient, Dentistry, Thalassemia

The family of the 3 Iraqi patients was counseled and explained in detail about all the pros and cons pertaining to stem cell transplant.

Key Points: 
  • The family of the 3 Iraqi patients was counseled and explained in detail about all the pros and cons pertaining to stem cell transplant.
  • After getting informed consent, all three were admitted for a matched sibling donor stem cell transplant, which went off successfully.
  • Speaking about the rare BMT procedure, Dr Vikas Dua said, "The uniqueness about these 3 patients was their younger age.
  • Fortis Gurugram has a dedicated team of Hematologists alongwith the best of medical infrastructure to treat the most complex cases.

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Friday, August 11, 2023
GMP, Mayo Clinic, GE HealthCare, Safety, Glomus tumor, Doctor of Philosophy, Audit committee, Medicare, Journal, CATX, Patient, Investment, RLS, R, ED, NYSE, Brain, Prostate cancer, Centers for Medicare & Medicaid Services, University, Viewpoint, Fortis Healthcare, Research, Nuclear medicine, Rated R, Radiosurgery, Radiation, Knowledge, Growth, FDA, Bander, SPECT, GT, Roche, Isotopes of thorium, USP, 1991 World Sportscar Championship, Documentation, International Symposium on Endovascular Therapy, Neurosurgery, Therapy, Joint Commission, Isotopes of caesium, SNMMI, MC1R, Molecular imaging, PET, University of Iowa, CDMO, Melanoma, Medical imaging, Pharmaceutical industry, Management, Health insurance, MD, Brachytherapy, Operation

RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.

Key Points: 
  • RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.
  • With a strong team in place, we’re focused on securing new business and re-gaining old business.
  • For the first half of fiscal 2023 ended June 30, 2023, revenue decreased 23% to $4.2 million versus $5.4 million in the prior year comparable period.
  • Prostate brachytherapy represented 42% of total revenue for the first six months of fiscal 2023 compared to 73% for the first six months of fiscal 2022.

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Retrieved on: 
Wednesday, June 21, 2023
Society, Mayo Clinic, University, MC1R, Neoplasm, Fortis Healthcare, Glomus tumor, Molecular imaging, Ligand, Cancer, Lead, Fast Track, Research, PB, Perspective, Immunotherapy, Teaching hospital, CDMO, CATX, Patient, Melanoma, FMRI, SSTR2, Therapy, IND, Isotope, NYSE, Pharmaceutical industry, Medical imaging, IOWA

The first product candidate, VMT-α-NET, is a result of Perspective’s intensive in-house research and development efforts to develop a best-in-class radiopeptide.

Key Points: 
  • The first product candidate, VMT-α-NET, is a result of Perspective’s intensive in-house research and development efforts to develop a best-in-class radiopeptide.
  • Both US trials will be supplied with finished drug product from Perspective’s GMP manufacturing facility in Coralville, IA.
  • “These clinical trials represent a significant advancement in our relentless pursuit of innovative and potent treatments for cancer," said Markus Puhlmann, Chief Medical Officer at Perspective.
  • The targeted alpha-particle therapies that are being developed at Perspective have the potential to revolutionize the treatment of these and many other cancers.

ICPO Foundation and FMRI Enter Strategic Partnership to Promote International Education Standards and Support Establishment of new Theranostics Reference Centers in India

Retrieved on: 
Wednesday, June 21, 2023
Research, Technology, Other Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Partnership, Meridian International Center, Education, Fortis Healthcare, RPO, Cancer, Nuclear medicine, Medicine, Patient, FMRI, Knowledge, ICPO, Nursing

The International Centers for Precision Oncology (ICPO) Foundation and Fortis Memorial Research Institute (FMRI) today announced a reference center collaboration to promote international education standards in Radiomolecular Precision Oncology (RPO) and support the establishment of new Theranostics Centers in India.

Key Points: 
  • The International Centers for Precision Oncology (ICPO) Foundation and Fortis Memorial Research Institute (FMRI) today announced a reference center collaboration to promote international education standards in Radiomolecular Precision Oncology (RPO) and support the establishment of new Theranostics Centers in India.
  • ICPO Foundation and FMRI have signed an agreement to advance education and infrastructure in RPO through their combined medical and scientific expertise.
  • As part of this collaboration, ICPO and FMRI will work together to establish a state-of-the-art Theranostics Reference Center at FMRI, which will serve as a hub for RPO education, research, and clinical practice in India.
  • Through the partnership, ICPO Foundation will leverage its expertise and the ICPO Academy for Theranostics Platform to provide cutting-edge education and training resources to FMRI and its network of healthcare professionals.

Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference

Retrieved on: 
Thursday, June 8, 2023
Fortis Healthcare, Mayo Clinic, University of Alabama, Drug development, SNMMI, University, Photon, Half-life, Molecular imaging, Cancer, Fortis, Isotopes of lead, Radiochemistry, Research, Nuclear medicine, Doctor of Philosophy, Perspective, All but dissertation, Science, CATX, Patient, Clinical research, MN, Parul, Clinical professor, Tat, Integration, Therapy, EC, Health, Conference, NYSE, SPECT, Safety, Medical imaging, Pharmaceutical industry, Medical device, Melanoma, IOWA

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will have four presentations at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging (SNMMI) Conference being held in Chicago from June 24-27, 2023.

Key Points: 
  • RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will have four presentations at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging (SNMMI) Conference being held in Chicago from June 24-27, 2023.
  • "Our team at Perspective Therapeutics continues to make progress across all aspects of development, including the generation of promising clinical data.
  • We are delighted to present the latest research on our products at the SNMMI annual conference.
  • This will be a presentation of the initial First-in-Human data from Perspective’s MC1R-targeted VMT01/02 imaging study conducted at the Mayo Clinic, Rochester.

Fortis Healthcare recognized for its contribution in positioning India as the Medical Tourism Hub; Conferred with 7 Awards

Retrieved on: 
Tuesday, May 23, 2023
Fortis Healthcare, Audit committee, Surgical oncology, FICCI, Travel, Interventional cardiology, Ernst & Young, The Honourable, Health, International Summit Council for Peace, Oncology, Government, Hospital, Patient, MD, Cardiology, Okhla, Noida, Medical tourism, Nursing, Fortis, Neuroscience

NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India. Fortis bagged awards in 7 out of 12 categories - out of which Fortis Memorial Research Institute, Gurugram bagged 4 awards in Bone Marrow Transplant, Medical Oncology, Surgical Oncology and Neurosciences; Fortis Escorts Heart Institute, Okhla bagged 2 awards in Paediatric Cardiac Sciences (Cardiology and Cardiac Surgery) and Interventional Cardiology and Fortis Hospital, Noida bagged 1 award in liver transplant.

Key Points: 
  • Fortis was awarded by Advantage Health Care India - an International Summit, which was organized from 26th - 28thApril 2023
    NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India.
  • Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said "This is a proud moment for the Fortis group.
  • We have always been at the forefront to provide the best of medical services to foreign patients who avail our medical services.
  • The cost-effective treatment, highly skilled healthcare professionals, world-class infrastructure, easy travel accessibility along with language proficiency makes Fortis the most preferred destination for medical tourism."

Fortis Healthcare recognized for its contribution in positioning India as the Medical Tourism Hub; Conferred with 7 Awards

Retrieved on: 
Tuesday, May 23, 2023
Fortis Healthcare, Audit committee, Surgical oncology, FICCI, Travel, Interventional cardiology, Ernst & Young, The Honourable, Health, International Summit Council for Peace, Oncology, Government, Hospital, Patient, MD, Cardiology, Okhla, Noida, Medical tourism, Nursing, Fortis, Neuroscience

NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India. Fortis bagged awards in 7 out of 12 categories - out of which Fortis Memorial Research Institute, Gurugram bagged 4 awards in Bone Marrow Transplant, Medical Oncology, Surgical Oncology and Neurosciences; Fortis Escorts Heart Institute, Okhla bagged 2 awards in Paediatric Cardiac Sciences (Cardiology and Cardiac Surgery) and Interventional Cardiology and Fortis Hospital, Noida bagged 1 award in liver transplant.

Key Points: 
  • Fortis was awarded by Advantage Health Care India - an International Summit, which was organized from 26th - 28thApril 2023
    NEW DELHI, May 23, 2023 /PRNewswire/ -- India's leading hospital chain, Fortis Healthcare has been recognized for its contribution in positioning India as the preferred medical tourism destination by Advantage Health Care India.
  • Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said "This is a proud moment for the Fortis group.
  • We have always been at the forefront to provide the best of medical services to foreign patients who avail our medical services.
  • The cost-effective treatment, highly skilled healthcare professionals, world-class infrastructure, easy travel accessibility along with language proficiency makes Fortis the most preferred destination for medical tourism."